Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Anavex FDA Alzheimer’s Trails Proposals

It should be noted (read carefully) that Juan Carlos Lopez-Talavera, MD, PhD, Executive Vice President, Head of Research and Development, of Anavex Life Sciences Corp. has provided “additional comments on the FDA's revised draft guidance for developing drugs for the treatment of early Alzheimer's Disease (AD).“

Access the PDF here:
https://downloads.regulations.gov/FDA-2013-D-0077-0092/attach0ment_1.pdf

Dr. Lopez-Talavera has made six specific new proposals to the FDA on how drugs treating Alzheimer’s (such as his company’s blarcamesine) should be evaluated in clinical trials.

To be informed on the matter, read and consider the proposals. Understand, none of these would have been proposed without an understanding that they will facilitate the FDA’s approval of blarcamesine. Consider closely proposals 4, 5 and 6. Dr. Lopez-Talavera has information, understands that blarcamesine will favorably comply with these.